KMB

Business Context and Reporting Period

Company: Kimberly-Clark Corporation
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2006
Business Overview: The Corporation operates four global business segments: Personal Care, Consumer Tissue, K-C Professional & Other, and Health Care. The company is executing a multi-year strategic cost reduction plan aimed at streamlining operations and reducing the workforce by approximately 10% by the end of 2008.

Key Financial Metrics

Note: Total Debt calculated as Debt payable within one year ($1,360.6M) plus Long-Term Debt ($2,272.1M) as of Sept 30, 2006.

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 5.2% in Q3 2006 and 4.6% for the first nine months, driven by volume growth, price increases, and favorable currency effects (approx. 2% impact in Q3).
• Profitability: Q3 Operating Profit rose 13.3% year-over-year, aided by lower strategic cost reduction charges ($45M less than prior year) and cost savings. However, 9-month Operating Profit declined 14.2% due to significantly higher strategic cost reduction charges ($253.6M increase vs. 2005).
• Net Income: Q3 Net Income increased 12.0% to $364.2M. 9-month Net Income decreased 15.1% to $1,016.9M, impacted by higher restructuring charges and increased stock-based compensation expenses following the adoption of SFAS 123R.
• Segment Performance:
  • Personal Care: Sales up 6.7% (Q3) driven by volume growth in North America and emerging markets.
  • Consumer Tissue: Sales up 3.1% (Q3) due to price increases, though volumes declined in North America and Europe.
  • Health Care: Sales up 7.9% (Q3) with strong volume growth in face masks and gloves.
• Cost Inflation: Raw material costs (fiber, polymers, superabsorbents) and energy costs increased significantly, offsetting some margin gains.

Guidance, Outlook, and Risks

• Strategic Cost Reductions: The company expects cumulative pretax charges of $1.0 to $1.1 billion through 2008, with annual pretax savings of at least $350 million expected in 2009. Full-year 2006 charges are expected to total approximately $500 million.
• Capital Allocation:
  • Capital Spending: Targeted between $900 million and $1 billion for the full year 2006.
  • Share Repurchases: Targeted at $750 million for the full year 2006. Approximately $464 million spent in the first nine months.
  • Dividends: Cash dividends declared were $0.49 per share for Q3 2006.
• Outlook: Management expects solid top-line growth in Q4 driven by emerging markets, price increases, and volume growth. However, inflation (pulp, polymer resins) is expected to continue impacting costs.
• Accounting Changes: Adoption of SFAS 123R (Stock-Based Compensation) reduced net income by $15.6 million for the nine months ended Sept 30, 2006. Adoption of SFAS 158 (Pension Accounting) is expected to increase liabilities by over $350 million upon implementation in 2007.
• Risks: Fluctuations in raw material prices (oil-based products, pulp), foreign currency exchange rates, and competitive pressures on selling prices.

Investor Verification Checklist

• Restructuring Progress: Verify the pace of the strategic cost reduction plan and the realization of the projected $350 million annual savings by 2009.
• Volume Trends: Monitor the rebound in Consumer Tissue volumes in North America and Europe following price increases.
• Input Costs: Track the trajectory of pulp and polymer resin costs, which are currently offsetting margin improvements.
• Equity Affiliate Performance: Review the performance of Kimberly-Clark de Mexico (KCM), which contributed significantly to equity income, and the impact of its recent pulp/paper business sale.
• Debt Levels: Confirm the trajectory of total debt reduction, which stood at $4.4 billion (including preferred securities) as of Sept 30, 2006.